Down And Up — It's A Wild Ride

From 25% Down to 17% Up: My Wild Ride with Moleculin Biotech (MBRX)

Posted: September 22, 2025

Hey folks, it's your friendly neighborhood stock dabbler here—let's talk about one of those "heart-stopping but ultimately rewarding" trades that keeps us all coming back to the market. If you've ever bought a speculative biotech play and watched it nosedive, then claw its way back, this one's for you. Today, I'm pulling back the curtain on my tiny position in Moleculin Biotech (MBRX), a small-cap oncology innovator that's been on my radar for its promising (but risky) pipeline targeting hard-to-treat cancers.

I scooped up 2 shares back on July 2, 2025, at an average cost of $0.34 per share—total investment: about $0.68. Nothing to write home about, but hey, every position starts somewhere. Fast-forward to today, September 22, 2025, and the stock's trading at $0.4054, putting my little stake at $0.81 and me up +$0.12 (+17.50%). Sweet, right? But oh boy, the journey wasn't all green candles...

The Gut-Check Low: Down 25% in a Blink

Biotech stocks are notorious for their volatility—news cycles, trial updates, and sector sentiment can swing 'em like a pendulum. Sure enough, by August 5, 2025, MBRX cratered to an intraday low of $0.2550. At that point? My position was worth a measly $0.51, leaving me down -$0.17 (-25%) from my cost basis.

Oof. That's the kind of drawdown that makes you question your life choices over a cold coffee. Was it a broader market dip? (Yeah, biotech got hammered that week amid rising rates chatter.) A company-specific hiccup? (Moleculin's been navigating FDA feedback on its lead candidate, annamycin.) Or just the brutal reality of penny-stock land? All of the above, probably. But here's the silver lining: I held. No panic sells, no FOMO regrets—just rode the wave.

The Rebound: Back in the Green and Loving It

Cut to now, and MBRX has staged a solid ~59% recovery from that August trough. Why the bounce? A mix of positive analyst notes on their myelodysplastic syndrome data, some short squeeze vibes in the micro-cap space, and the eternal hope of biotech bulls. My unrealized gain isn't life-changing (yet), but it's a reminder that patience can pay off—even in the wild west of sub-$1 stocks.

Quick Numbers Breakdown

Date/Event	Price/Share	Position Value (2 Shares)	Gain/Loss from Cost	% Change
Purchase (Jul 2, 2025)	$0.34	$0.68	$0.00	0%
Worst Low (Aug 5, 2025)	$0.2550	$0.51	-$0.17	-25%
Today (Sep 22, 2025)	$0.4054	$0.81	+$0.12	+17.50%

(Data pulled from Nasdaq / Yahoo Finance—markets move fast, so DYOR!)

The Takeaway: Volatility is the Price of Admission

Look, I'm no Warren Buffett—this is just one micro-position in a diversified bag. But stories like this highlight why I love (and sometimes hate) trading small biotechs: massive downside risk, but asymmetric upside if a trial hits. MBRX could still flop (disclaimers: not financial advice, past performance ain't future results), but for now, it's a win that feels earned.

What's your biggest "down big, up bigger" trade? Drop it in the comments—let's commiserate and celebrate. And if you're eyeing MBRX, check their latest on annamycin or their WP1066 program. Who knows? Maybe we'll all be toasting Phase 3 data someday.

Stay nimble,
Shaneman007

P.S. If you enjoyed this, smash that like/share button—helps more folks navigate the biotech rollercoaster.